 | • レポートコード：MRC2Q12-16736 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、127ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、膀胱疾患治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 膀胱疾患治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 膀胱疾患治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 膀胱疾患治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの膀胱疾患治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の膀胱疾患治療薬の売上および2028年までの予測に焦点を当てています。 膀胱疾患治療薬のグローバル主要企業には、Merck、Astellas Pharma Inc.、Bristol-myers Squibb Company、Boston Scientific Corporation、Viatris Inc.、Abbvie、Axonics, Inc.、Blue Wind Medical、Coloplast Corp.、Gaylord Chemical Company, Llc、Johnson & Johnson Services, Inc.、Kyorin Pharmaceutical Co., Ltd.、Laborie、Medtronic、Pfizer Inc.、Valencia Technologies、Sun Phamaceutical Industries Ltd.、Swati Spentose、Urovant Sciences、Zydus Groupなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 膀胱疾患治療薬市場は、タイプとアプリケーションによって区分されます。世界の膀胱疾患治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 経口、注射 【アプリケーション別セグメント】 過活動膀胱、尿失禁、膀胱炎、間質性膀胱炎、膀胱がん、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 膀胱疾患治療薬製品概要 - タイプ別市場（経口、注射） - アプリケーション別市場（過活動膀胱、尿失禁、膀胱炎、間質性膀胱炎、膀胱がん、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の膀胱疾患治療薬販売量予測2017-2028 - 世界の膀胱疾患治療薬売上予測2017-2028 - 膀胱疾患治療薬の地域別販売量 - 膀胱疾患治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別膀胱疾患治療薬販売量 - 主要メーカー別膀胱疾患治療薬売上 - 主要メーカー別膀胱疾患治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（経口、注射） - 膀胱疾患治療薬のタイプ別販売量 - 膀胱疾患治療薬のタイプ別売上 - 膀胱疾患治療薬のタイプ別価格 ・アプリケーション別市場規模（過活動膀胱、尿失禁、膀胱炎、間質性膀胱炎、膀胱がん、その他） - 膀胱疾患治療薬のアプリケーション別販売量 - 膀胱疾患治療薬のアプリケーション別売上 - 膀胱疾患治療薬のアプリケーション別価格 ・北米市場 - 北米の膀胱疾患治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の膀胱疾患治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの膀胱疾患治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の膀胱疾患治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の膀胱疾患治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の膀胱疾患治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の膀胱疾患治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の膀胱疾患治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの膀胱疾患治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の膀胱疾患治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Merck、Astellas Pharma Inc.、Bristol-myers Squibb Company、Boston Scientific Corporation、Viatris Inc.、Abbvie、Axonics, Inc.、Blue Wind Medical、Coloplast Corp.、Gaylord Chemical Company, Llc、Johnson & Johnson Services, Inc.、Kyorin Pharmaceutical Co., Ltd.、Laborie、Medtronic、Pfizer Inc.、Valencia Technologies、Sun Phamaceutical Industries Ltd.、Swati Spentose、Urovant Sciences、Zydus Group ・産業チェーン及び販売チャネル分析 - 膀胱疾患治療薬の産業チェーン分析 - 膀胱疾患治療薬の原材料 - 膀胱疾患治療薬の生産プロセス - 膀胱疾患治療薬の販売及びマーケティング - 膀胱疾患治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 膀胱疾患治療薬の産業動向 - 膀胱疾患治療薬のマーケットドライバー - 膀胱疾患治療薬の課題 - 膀胱疾患治療薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Bladder Diseases Drug estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Bladder Diseases Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Bladder Diseases Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Bladder Diseases Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Bladder Diseases Drug include Merck, Astellas Pharma Inc., Bristol-myers Squibb Company, Boston Scientific Corporation, Viatris Inc., Abbvie, Axonics, Inc., Blue Wind Medical and Coloplast Corp., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Bladder Diseases Drug companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Bladder Diseases Drug market. Further, it explains the major drivers and regional dynamics of the global Bladder Diseases Drug market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Merck
Astellas Pharma Inc.
Bristol-myers Squibb Company
Boston Scientific Corporation
Viatris Inc.
Abbvie
Axonics, Inc.
Blue Wind Medical
Coloplast Corp.
Gaylord Chemical Company, Llc
Johnson & Johnson Services, Inc.
Kyorin Pharmaceutical Co., Ltd.
Laborie
Medtronic
Pfizer Inc.
Valencia Technologies
Sun Phamaceutical Industries Ltd.
Swati Spentose
Urovant Sciences
Zydus Group
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Bladder Diseases Drug Segment by Type
Oral
Injection
Bladder Diseases Drug Segment by Application
Overactive Bladder
Urinary Incontinence
Cystitis
Interstitial Cystitis
Bladder Cancer
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Bladder Diseases Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Bladder Diseases Drug market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Bladder Diseases Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Bladder Diseases Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Bladder Diseases Drug revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Bladder Diseases Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Bladder Diseases Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Merck, Astellas Pharma Inc., Bristol-myers Squibb Company, Boston Scientific Corporation, Viatris Inc., Abbvie, Axonics, Inc., Blue Wind Medical and Coloplast Corp., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Bladder Diseases Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Bladder Diseases Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Bladder Diseases Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Bladder Diseases Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Bladder Diseases Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Overactive Bladder
1.3.3 Urinary Incontinence
1.3.4 Cystitis
1.3.5 Interstitial Cystitis
1.3.6 Bladder Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Bladder Diseases Drug Market Perspective (2017-2028)
2.2 Bladder Diseases Drug Growth Trends by Region
2.2.1 Bladder Diseases Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Bladder Diseases Drug Historic Market Size by Region (2017-2022)
2.2.3 Bladder Diseases Drug Forecasted Market Size by Region (2023-2028)
2.3 Bladder Diseases Drug Market Dynamics
2.3.1 Bladder Diseases Drug Industry Trends
2.3.2 Bladder Diseases Drug Market Drivers
2.3.3 Bladder Diseases Drug Market Challenges
2.3.4 Bladder Diseases Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Bladder Diseases Drug Players by Revenue
3.1.1 Global Top Bladder Diseases Drug Players by Revenue (2017-2022)
3.1.2 Global Bladder Diseases Drug Revenue Market Share by Players (2017-2022)
3.2 Global Bladder Diseases Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Bladder Diseases Drug Revenue
3.4 Global Bladder Diseases Drug Market Concentration Ratio
3.4.1 Global Bladder Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Bladder Diseases Drug Revenue in 2021
3.5 Bladder Diseases Drug Key Players Head office and Area Served
3.6 Key Players Bladder Diseases Drug Product Solution and Service
3.7 Date of Enter into Bladder Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Bladder Diseases Drug Breakdown Data by Type
4.1 Global Bladder Diseases Drug Historic Market Size by Type (2017-2022)
4.2 Global Bladder Diseases Drug Forecasted Market Size by Type (2023-2028)
5 Bladder Diseases Drug Breakdown Data by Application
5.1 Global Bladder Diseases Drug Historic Market Size by Application (2017-2022)
5.2 Global Bladder Diseases Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Bladder Diseases Drug Market Size (2017-2028)
6.2 North America Bladder Diseases Drug Market Size by Type
6.2.1 North America Bladder Diseases Drug Market Size by Type (2017-2022)
6.2.2 North America Bladder Diseases Drug Market Size by Type (2023-2028)
6.2.3 North America Bladder Diseases Drug Market Share by Type (2017-2028)
6.3 North America Bladder Diseases Drug Market Size by Application
6.3.1 North America Bladder Diseases Drug Market Size by Application (2017-2022)
6.3.2 North America Bladder Diseases Drug Market Size by Application (2023-2028)
6.3.3 North America Bladder Diseases Drug Market Share by Application (2017-2028)
6.4 North America Bladder Diseases Drug Market Size by Country
6.4.1 North America Bladder Diseases Drug Market Size by Country (2017-2022)
6.4.2 North America Bladder Diseases Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Bladder Diseases Drug Market Size (2017-2028)
7.2 Europe Bladder Diseases Drug Market Size by Type
7.2.1 Europe Bladder Diseases Drug Market Size by Type (2017-2022)
7.2.2 Europe Bladder Diseases Drug Market Size by Type (2023-2028)
7.2.3 Europe Bladder Diseases Drug Market Share by Type (2017-2028)
7.3 Europe Bladder Diseases Drug Market Size by Application
7.3.1 Europe Bladder Diseases Drug Market Size by Application (2017-2022)
7.3.2 Europe Bladder Diseases Drug Market Size by Application (2023-2028)
7.3.3 Europe Bladder Diseases Drug Market Share by Application (2017-2028)
7.4 Europe Bladder Diseases Drug Market Size by Country
7.4.1 Europe Bladder Diseases Drug Market Size by Country (2017-2022)
7.4.2 Europe Bladder Diseases Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Bladder Diseases Drug Market Size (2017-2028)
8.2 Asia-Pacific Bladder Diseases Drug Market Size by Type
8.2.1 Asia-Pacific Bladder Diseases Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Bladder Diseases Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Bladder Diseases Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Bladder Diseases Drug Market Size by Application
8.3.1 Asia-Pacific Bladder Diseases Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Bladder Diseases Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Bladder Diseases Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Bladder Diseases Drug Market Size by Region
8.4.1 Asia-Pacific Bladder Diseases Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Bladder Diseases Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Bladder Diseases Drug Market Size (2017-2028)
9.2 Latin America Bladder Diseases Drug Market Size by Type
9.2.1 Latin America Bladder Diseases Drug Market Size by Type (2017-2022)
9.2.2 Latin America Bladder Diseases Drug Market Size by Type (2023-2028)
9.2.3 Latin America Bladder Diseases Drug Market Share by Type (2017-2028)
9.3 Latin America Bladder Diseases Drug Market Size by Application
9.3.1 Latin America Bladder Diseases Drug Market Size by Application (2017-2022)
9.3.2 Latin America Bladder Diseases Drug Market Size by Application (2023-2028)
9.3.3 Latin America Bladder Diseases Drug Market Share by Application (2017-2028)
9.4 Latin America Bladder Diseases Drug Market Size by Country
9.4.1 Latin America Bladder Diseases Drug Market Size by Country (2017-2022)
9.4.2 Latin America Bladder Diseases Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Bladder Diseases Drug Market Size (2017-2028)
10.2 Middle East & Africa Bladder Diseases Drug Market Size by Type
10.2.1 Middle East & Africa Bladder Diseases Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Bladder Diseases Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Bladder Diseases Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Bladder Diseases Drug Market Size by Application
10.3.1 Middle East & Africa Bladder Diseases Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Bladder Diseases Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Bladder Diseases Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Bladder Diseases Drug Market Size by Country
10.4.1 Middle East & Africa Bladder Diseases Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Bladder Diseases Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Merck Business Overview
11.1.3 Merck Bladder Diseases Drug Introduction
11.1.4 Merck Revenue in Bladder Diseases Drug Business (2017-2022)
11.1.5 Merck Recent Developments
11.2 Astellas Pharma Inc.
11.2.1 Astellas Pharma Inc. Company Details
11.2.2 Astellas Pharma Inc. Business Overview
11.2.3 Astellas Pharma Inc. Bladder Diseases Drug Introduction
11.2.4 Astellas Pharma Inc. Revenue in Bladder Diseases Drug Business (2017-2022)
11.2.5 Astellas Pharma Inc. Recent Developments
11.3 Bristol-myers Squibb Company
11.3.1 Bristol-myers Squibb Company Company Details
11.3.2 Bristol-myers Squibb Company Business Overview
11.3.3 Bristol-myers Squibb Company Bladder Diseases Drug Introduction
11.3.4 Bristol-myers Squibb Company Revenue in Bladder Diseases Drug Business (2017-2022)
11.3.5 Bristol-myers Squibb Company Recent Developments
11.4 Boston Scientific Corporation
11.4.1 Boston Scientific Corporation Company Details
11.4.2 Boston Scientific Corporation Business Overview
11.4.3 Boston Scientific Corporation Bladder Diseases Drug Introduction
11.4.4 Boston Scientific Corporation Revenue in Bladder Diseases Drug Business (2017-2022)
11.4.5 Boston Scientific Corporation Recent Developments
11.5 Viatris Inc.
11.5.1 Viatris Inc. Company Details
11.5.2 Viatris Inc. Business Overview
11.5.3 Viatris Inc. Bladder Diseases Drug Introduction
11.5.4 Viatris Inc. Revenue in Bladder Diseases Drug Business (2017-2022)
11.5.5 Viatris Inc. Recent Developments
11.6 Abbvie
11.6.1 Abbvie Company Details
11.6.2 Abbvie Business Overview
11.6.3 Abbvie Bladder Diseases Drug Introduction
11.6.4 Abbvie Revenue in Bladder Diseases Drug Business (2017-2022)
11.6.5 Abbvie Recent Developments
11.7 Axonics, Inc.
11.7.1 Axonics, Inc. Company Details
11.7.2 Axonics, Inc. Business Overview
11.7.3 Axonics, Inc. Bladder Diseases Drug Introduction
11.7.4 Axonics, Inc. Revenue in Bladder Diseases Drug Business (2017-2022)
11.7.5 Axonics, Inc. Recent Developments
11.8 Blue Wind Medical
11.8.1 Blue Wind Medical Company Details
11.8.2 Blue Wind Medical Business Overview
11.8.3 Blue Wind Medical Bladder Diseases Drug Introduction
11.8.4 Blue Wind Medical Revenue in Bladder Diseases Drug Business (2017-2022)
11.8.5 Blue Wind Medical Recent Developments
11.9 Coloplast Corp.
11.9.1 Coloplast Corp. Company Details
11.9.2 Coloplast Corp. Business Overview
11.9.3 Coloplast Corp. Bladder Diseases Drug Introduction
11.9.4 Coloplast Corp. Revenue in Bladder Diseases Drug Business (2017-2022)
11.9.5 Coloplast Corp. Recent Developments
11.10 Gaylord Chemical Company, Llc
11.10.1 Gaylord Chemical Company, Llc Company Details
11.10.2 Gaylord Chemical Company, Llc Business Overview
11.10.3 Gaylord Chemical Company, Llc Bladder Diseases Drug Introduction
11.10.4 Gaylord Chemical Company, Llc Revenue in Bladder Diseases Drug Business (2017-2022)
11.10.5 Gaylord Chemical Company, Llc Recent Developments
11.11 Johnson & Johnson Services, Inc.
11.11.1 Johnson & Johnson Services, Inc. Company Details
11.11.2 Johnson & Johnson Services, Inc. Business Overview
11.11.3 Johnson & Johnson Services, Inc. Bladder Diseases Drug Introduction
11.11.4 Johnson & Johnson Services, Inc. Revenue in Bladder Diseases Drug Business (2017-2022)
11.11.5 Johnson & Johnson Services, Inc. Recent Developments
11.12 Kyorin Pharmaceutical Co., Ltd.
11.12.1 Kyorin Pharmaceutical Co., Ltd. Company Details
11.12.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
11.12.3 Kyorin Pharmaceutical Co., Ltd. Bladder Diseases Drug Introduction
11.12.4 Kyorin Pharmaceutical Co., Ltd. Revenue in Bladder Diseases Drug Business (2017-2022)
11.12.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments
11.13 Laborie
11.13.1 Laborie Company Details
11.13.2 Laborie Business Overview
11.13.3 Laborie Bladder Diseases Drug Introduction
11.13.4 Laborie Revenue in Bladder Diseases Drug Business (2017-2022)
11.13.5 Laborie Recent Developments
11.14 Medtronic
11.14.1 Medtronic Company Details
11.14.2 Medtronic Business Overview
11.14.3 Medtronic Bladder Diseases Drug Introduction
11.14.4 Medtronic Revenue in Bladder Diseases Drug Business (2017-2022)
11.14.5 Medtronic Recent Developments
11.15 Pfizer Inc.
11.15.1 Pfizer Inc. Company Details
11.15.2 Pfizer Inc. Business Overview
11.15.3 Pfizer Inc. Bladder Diseases Drug Introduction
11.15.4 Pfizer Inc. Revenue in Bladder Diseases Drug Business (2017-2022)
11.15.5 Pfizer Inc. Recent Developments
11.16 Valencia Technologies
11.16.1 Valencia Technologies Company Details
11.16.2 Valencia Technologies Business Overview
11.16.3 Valencia Technologies Bladder Diseases Drug Introduction
11.16.4 Valencia Technologies Revenue in Bladder Diseases Drug Business (2017-2022)
11.16.5 Valencia Technologies Recent Developments
11.17 Sun Phamaceutical Industries Ltd.
11.17.1 Sun Phamaceutical Industries Ltd. Company Details
11.17.2 Sun Phamaceutical Industries Ltd. Business Overview
11.17.3 Sun Phamaceutical Industries Ltd. Bladder Diseases Drug Introduction
11.17.4 Sun Phamaceutical Industries Ltd. Revenue in Bladder Diseases Drug Business (2017-2022)
11.17.5 Sun Phamaceutical Industries Ltd. Recent Developments
11.18 Swati Spentose
11.18.1 Swati Spentose Company Details
11.18.2 Swati Spentose Business Overview
11.18.3 Swati Spentose Bladder Diseases Drug Introduction
11.18.4 Swati Spentose Revenue in Bladder Diseases Drug Business (2017-2022)
11.18.5 Swati Spentose Recent Developments
11.19 Urovant Sciences
11.19.1 Urovant Sciences Company Details
11.19.2 Urovant Sciences Business Overview
11.19.3 Urovant Sciences Bladder Diseases Drug Introduction
11.19.4 Urovant Sciences Revenue in Bladder Diseases Drug Business (2017-2022)
11.19.5 Urovant Sciences Recent Developments
11.20 Zydus Group
11.20.1 Zydus Group Company Details
11.20.2 Zydus Group Business Overview
11.20.3 Zydus Group Bladder Diseases Drug Introduction
11.20.4 Zydus Group Revenue in Bladder Diseases Drug Business (2017-2022)
11.20.5 Zydus Group Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer